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Blood Urea Nitrogen
A Marker for Adverse Effects
of Loop Diuretics?*
JoAnn Lindenfeld, MD,† Robert W. Schrier, MD‡
Aurora, Colorado
Loop diuretics are used in patients with heart failure (HF)
to relieve symptoms of systemic and pulmonary venous
congestion. Despite their nearly universal use for this
indication, loop diuretics have not been shown to improve
survival—indeed, a number of recent studies suggest an
adverse relationship between the use of loop diuretics and
survival (1–3). This is plausible because loop diuretics block
sodium chloride absorption at the macula densa in the thick
ascending limb of the loop of Henle, activating the renin-
angiotensin-aldosterone system (RAAS) and potentially
exacerbating HF (4). Few data exist to inform providers
how to use loop diuretics to provide the greatest symptom-
atic benefit with the least adverse effect. In this issue of the
Journal, Testani et al. (5) have provided insight into this
See page 375
difficult therapeutic dilemma. They analyzed data from the
BEST (Beta-Blocker Evaluation of Survival Trial) to deter-
mine whether the blood urea nitrogen (BUN), used as a
surrogate marker of neurohormonal activation, might iden-
tify patients most likely to have adverse effects from high-
dose loop diuretics (HDLDs). The BEST was a National
Heart, Lung, and Blood Institute–sponsored multicenter,
randomized, placebo-controlled trial comparing a beta-
adrenergic blocker, bucindolol, with placebo in patients
with New York Heart Association functional class III or IV
heart failure, a left ventricular ejection fraction of 35%,
and who were taking an angiotensin-converting enzyme
inhibitor for1 month (6). The BEST did not demonstrate
a beneficial effect of bucindolol for the primary endpoint of
all-cause mortality, so all subjects could be combined for this
analysis. Testani et al. (5) showed that HDLDs (defined as
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low-dose loop diuretics (LDLDs) were not associated with
an adverse effect on mortality in the overall BEST popula-
tion. However, with correction for baseline characteristics,
HDLDs were associated with an adverse effect on mortality
in subjects with a BUN above the median (21 mg/dl), but a
beneficial effect on mortality in patients with a lower BUN.
The authors postulate that in the HF patients with the
higher BUN, neurohormonal activation with an HDLD
was greater than the withdrawal of neurohormonal activa-
tion resulting from decongestion, thus leading to a poorer
survival. In contrast, the balance in neurohormonal activation
with HDLDs and neurohormonal withdrawal was favorably
altered in the low BUN group, leading to improved survival.
This is an intriguing and novel hypothesis. Several important
concepts underlie the premise of this study including the
relationship of serum creatinine and BUN to the glomerular
filtration rate (GFR) and the complex relationship between
sodium and water reabsorption, urea reabsorption, and neuro-
hormonal activation in HF patients.
Serum creatinine has generally been used clinically to
estimate renal function in HF. Serum creatinine is freely
filtered at the glomerulus and not reabsorbed. However,
creatinine undergoes tubular secretion, and thus creatinine
clearance overestimates inulin clearance, the gold standard
for GFR (7). Likewise, because blood urea levels are affected
by protein intake, catabolism, and tubular reabsorption,
BUN is not as reliable a marker of renal function as the
GFR. However, based on the kidney’s handling of urea,
BUN more closely reflects neurohormonal activation than
changes in creatinine or the GFR (8). Urea is freely filtered
at the glomerlus and is not secreted, but is reabsorbed in
both the proximal and distal renal tubules. Urea reabsorp-
tion in the collecting duct is flow dependent so that more
urea is reabsorbed as urine flow rates decrease (7) (Fig. 1).
ccordingly, an elevation in BUN is a sign of severe HF and
as been shown to be a better prognosticator of mortality
nd rehospitalization than serum creatinine in several recent
F studies (9–13).
The complex relationship between sodium and water
eabsorption, neurohormonal activation, and BUN in pa-
ients with HF is outlined in Figure 2. Initially, HF causes
ow cardiac output and arterial underfilling, which unloads
he arterial baroreceptors and results in activation of both
he sympathetic nervous system (SNS) and the RAAS (14).
AAS activation increases sodium and water reabsorption
hroughout the nephron by activation of the proximal
ubular sodium-hydrogen exchanger and sodium-bicarbonate
otransporter and in the distal tubule and collecting ducts
hrough the sodium-chloride cotransporter and sodium
pithelial channels, respectively (15). Increased SNS activity
ncreases proximal tubular sodium transport by stimulation
f -adrenergic receptors, an effect independent of the GFR
(16). There is significant crosstalk between these systems.
Angiotensin II stimulates SNS activity, which activates the
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BUN and High-Dose Loop Diuretics July 19, 2011:383–5RAAS by a direct effect on -adrenergic receptors in the
uxtaglomerular apparatus (15,17). Moreover, arterial un-
erfilling stimulates arterial baroreceptor-mediated nonos-
Figure 1 Tubular Urea Reabsorption and
Flow Dependence of Urea Clearance
Inulin is freely filtered at the glomerulus and is neither secreted nor reab-
sorbed; thus, inulin clearance is the gold standard for the glomerular filtration
rate. Creatinine is also freely filtered and not reabsorbed, but creatinine is
secreted in the distal nephron, so creatinine clearance exceeds inulin clear-
ance. Urea is freely filtered and not secreted but undergoes reabsorption in the
distal nephron. Reabsorption of urea is flow dependent, so that more urea is reab-
sorbed at lower urine flow rates. Thus, high blood urea nitrogen is a marker for
more severe heart failure. Reprinted, with permission, from Berl et al. (7).
Figure 2 Interactions Between Neurohormonal Activation, Rena
Heart failure causes arterial underfilling, which results in neurohormonal activation
aldosterone system (RAAS), and nonosmotic arginine vasopressin (AVP) release. S
proximal tubule, leading to increased proximal tubular urea concentration and dec
tion. AVP also stimulates urea reabsorption in the collecting duct. The increased r
interstitial pressure, which further activates the RAAS. BUN  blood urea nitrogenotic arginine vasopressin (AVP) release, which causes further
olute-free water retention (17,18). Increased tubular reabsorp-
ion of sodium and water may elevate right atrial pressure with
n increase in renal venous and interstitial pressures and further
ctivation of the RAAS that, in turn, activates the SNS (19–21).
As with sodium and water reabsorption, increased reabsorp-
ion of urea in HF patients results from several different
echanisms. Reabsorption of sodium and water in the proxi-
al tubule leads to an increase in urea concentration, promot-
ng the passive reabsorption of urea. AVP secretion increases
rea reabsorption via the urea transporter in the inner medul-
ary collecting duct (18). As HF progresses, AVP-mediated
p-regulation of the renal urea transporters serves to increase
rea reabsorption in excess of any decrement in the GFR (18).
roximal tubular sodium and water reabsorption and AVP-
timulated water absorption in the distal tubule slow urine
ow, further increasing the reabsorption of urea (19). Thus, it
s reasonable to suggest that HF patients with an elevated
UN have a higher level of neurohormonal activation than
hose with a lower BUN. Certainly if HDLD are detrimental
n patients with a high BUN and more neurohormonal activation,
his high-risk group might be targeted for alternative methods of
odium and water removal such as ultrafiltration that may not lead
o additional neurohormonal activation (22,23).
Although this use of BUN is a novel and intriguing
oncept, this study is a first step that will require prospective
alidation. HDLDs may cause more neurohormonal acti-
ction, and Absorption of Urea
ing activation of the sympathetic nervous system (SNS), the renin-angiotensin-
d RAAS activation cause increased reabsorption of sodium and water in the
urine flow in the collecting duct with both resulting in increased urea reabsorp-
rption of sodium and water leads to increased right atrial pressure and renall Fun
includ
NS an
reased
eabso
.
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July 19, 2011:383–5 BUN and High-Dose Loop Diureticsvation than LDLDs. However, even LDLDs would be
expected to block sodium chloride transport in the ascend-
ing loop of Henle and the macula densa, resulting in
neurohormonal activation. The requirement for HDLDs
versus LDLDs is dependent on intrinsic renal function as
well as neurohormonal activation (24). Although the anal-
ysis corrected for baseline creatinine, it is possible that
serum creatinine might have been as discriminative as BUN.
If so, it would suggest that the underlying degree of renal
dysfunction, not neurohormonal activation, is the critical
predictive factor in the adverse effects of HDLDs. On the
other hand, those HF patients with the highest neurohor-
monal activation may also have the most renal vasoconstric-
tion and thus renal functional impairment. Plasma norepi-
nephrine concentration, the only direct marker of
neurohormonal activation in this study, was significantly
higher in the HDLD compared with the LDLD group and
in the high BUN compared with the low BUN group.
However, the levels of plasma norepinephrine in this study
did not indicate a high level of neurohormonal activation
and were closest to those reported in the SOLVD (Studies
of Left Ventricular Dysfunction) prevention rather than
treatment cohort (25). The plasma norepinephrine differ-
ences in the low and high BUN groups and in the HDLD
and LDLD groups are also less than the difference between
each of the quartiles in the VAL-HeFT (Valsartan in Heart
Failure Trial), suggesting that these high and low BUN
groups and HDLD and LDLD groups both have very
modest differences in neurohormonal activation (26). Fi-
nally, this study evaluated only baseline levels of BUN and
not the changes in BUN with increasing doses of diuretics.
Despite these issues, Testani et al. (5) are to be congrat-
ulated for this novel study suggesting that higher levels of
neurohormonal activation estimated by BUN might predict
potential adverse effects of loop diuretics. Future studies
establishing the value of BUN in predicting neurohormonal
activation and prospectively testing the hypothesis set out by
Testani et al. are eagerly anticipated.
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